Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, as always, rather modest. We plan to catch up on our reading, hold a listening party, promenade with the official mascot, and watch some footy on the telly. And what about you? This is a good time to boost the economy by purchasing holiday gifts. You could check to see where you are in line for a vaccine, or touch base with someone feeling isolated. Well, whatever you do, have a grand time. One further note: We are taking a two-week break, although trusted and esteemed colleagues will dish out doses of headlines in our absence. Meanwhile, enjoy and be safe — wear a mask. See you next year. …

A Food and Drug Administration advisory panel recommended the agency issue an emergency use authorization for a Covid-19 vaccine developed by Moderna (MRNA), all but guaranteeing the agency will do so, STAT explains. The authorization, expected on Friday, will mark the second Covid-19 vaccine cleared by the agency — and amount to one more step toward curbing a pandemic that has infected an estimated 17 million people and killed more than 300,000 in the U.S.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.